By: Benzinga
December 08, 2012 at 10:21 AM EST
Halozyme Announces Roche Filing to European Medicines Agency Triggers $4M Milestone Payment
Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today announced that Roche (OTC: RHHBY ) has submitted a line extension application to the European Medicines Agency for a subcutaneous (SC) formulation of MabThera® (rituxumab). The filing of the application triggered a $4 million milestone payment to Halozyme under the License
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here